Greece Patent System

Greece's pharmaceutical industry is primarily generic-focused, with some innovation-based pharmaceutical development: (1) ELPEN Pharmaceutical (Pikermi, Attica — one of Greece's largest domestic pharmaceutical companies; generics manufacturer for Greek and Balkan markets; some specialty pharmaceutical development): formulation patents for generic cardiovascular, CNS, and respiratory drugs; ELPEN manufactures under license and files some formulation process patents at OBI and EPO; (2) VIANEX/DEMO SA (Egaleo, Attica): Vianex is one of Greece's largest pharmaceutical marketing companies; Demo SA handles manufacturing; generic drug formulations for Greek market; manufacturing process patents; licensed products from multinational pharmaceutical companies; (3) GENEPHARM (Glyfada — generics, biosimilars): biosimilar development for European markets; biosimilar monoclonal antibody formulation patents; growing company filing patent applications in EU biosimilar regulatory pathway; (4) Pharmathen (Pallini, Attica — private equity owned; Greece's most internationally focused generic pharmaceutical company): Pharmathen has invested significantly in R&D, particularly in: drug delivery technology (modified-release formulations, depot injections, microparticle formulation patents for long-acting injectables); developed a long-acting injectable risperidone microsphere formulation (competing with Risperdal Consta); specialty generic formulations for difficult-to-formulate molecules; Pharmathen has been the most patent-active Greek domestic pharmaceutical company, with international PCT filings; (5) Hellenic Pasteur Institute (Athens — public health research institute affiliated with Institut Pasteur Paris): vaccine research; antimicrobial and antiviral research; diagnostics patent activity; (6) Academic pharma research: National and Kapodistrian University of Athens (NKUA) and Aristotle University of Thessaloniki (AUTH) generate pharmaceutical and biotech patent activity transferred via their tech transfer offices; (7) Farmaserv-Lilly (Kima — Greek Lilly affiliate; innovative drug clinical and registration activity; patents via Eli Lilly USA global patent portfolio).

Greece has developed a small but growing technology startup ecosystem, particularly following the severe economic crisis of 2010–2018 which paradoxically drove a generation of Greek professionals toward entrepreneurship: (1) Skroutz (Athens — Greece's largest price comparison and e-commerce marketplace; ~30 million monthly users in Greece, Cyprus, and Turkey; founded 2005 by Yiorgos Psaradellis and Giorgos Kostopoulos; approximately €10M ARR + marketplace revenue): Skroutz has developed proprietary technology in: product catalog management and matching algorithms (matching product listings from different retailers to a canonical product); price comparison search ranking and indexing algorithms; user review system with bot detection; click attribution technology for performance marketing; trade secret + copyright strategy rather than aggressive patent filing; (2) Upstream (Athens — mobile marketing technology; 'Mobile Marketing Experience' platform; works with mobile network operators globally; founded by Upstream Systems; portfolio company): API-based mobile marketing campaign management; fraud detection for mobile advertising (blocking fraudulent clicks/installs); carrier-grade messaging platform patents; mobile payment integration; (3) Workable (Athens + Boston — HR technology and recruiting software; acquired by Nikos Moraitakis and Spyros Magiatis; ~$50M ARR; manages the hiring workflow for thousands of companies): SaaS HR platform technology; AI-powered candidate matching and CV scoring algorithms; ATS (Applicant Tracking System) workflow automation; limited patent portfolio (primarily trade secret strategy); (4) Viva Wallet (Athens — cloud-based European card payment processing; raised ~$400M; now controlled by JP Morgan after 2022 investment): cloud payment processing architecture patents; card present and card not present payment processing; multi-currency settlement; PCI-DSS compliant payment tokenization patents; potential patent filing activity given payment industry IP environment; (5) Beat (Athens + Bogota — ride-hailing platform; formerly Taxibeat; Latin America focused; acquired by Free Now/BMW+Daimler): ride-hailing dispatch algorithm; driver-rider matching technology; Latin American market-specific fraud detection; (6) Athens tech ecosystem infrastructure: Endeavor Greece; Found.ation accelerator; Egg (Enter-Grow-Go) — National Bank of Greece accelerator; Hellenic Startups Association; Greek Research and Technology Network (GRNET); (7) COSMOS4U / LACROIX SPACE (Greece satellite technology): small satellite constellation technology for maritime AIS tracking; (8) ICEYE Greek partnership: SAR satellite imagery services for maritime domain awareness; (9) Singular Logic / Pylones: enterprise software for Greek government and utilities; limited patent activity (primarily trade secrets).

Greece's strongest traditional industries — food and tourism — present a distinctive IP profile centered more on geographical indications and trade marks than patents: (1) Geographical Indications (GI): Greece has registered numerous EU Protected Designations of Origin (PDO) and Protected Geographical Indications (PGI) for food products, which protect more economic value for Greek exporters than patents in these categories: Feta cheese (PDO — protected exclusively for Greek feta; EU Court of Justice confirmed GI protection vs. Danish/German imitation feta in 2005; annual Feta export value approximately €350–400M); Kalamata olives (PDO); Corinth currants (PGI — zante currant = smallest seedless raisin, specifically from Corinth region); Santorini wines (PDO — Assyrtiko variety from volcanic Santorini soil); Mastiha (PDO — mastic resin from Pistacia lentiscus var. chia trees on Chios island; used in foods, cosmetics, cosmeceuticals, dental hygiene); Kozani saffron (PDO — Greek Crocus sativus saffron from Kozani; among the world's most expensive spices); (2) Mastiha and biotech IP: Chios Mastiha Growers Association and related research institutions have filed patents related to mastiha extract applications: antibacterial/antimicrobial activity of mastiha (dental hygiene application patents); anti-inflammatory compounds isolated from mastiha resin; cosmeceutical applications (skin anti-aging, wound healing); VIORYL (Athens — Greek agro-chemical and pharmaceutical company; mastiha-based products IP); NKUA/AUTH research on mastiha bioactive compounds (triterpenoids, polymers); (3) JUMBO SA (Moschato, Athens — major Greek retail chain specializing in toys, baby products, seasonal items, and stationery; NZX listed): JUMBO holds product design registrations (EU Registered Community Designs) for its private label toys and decorative items — not patent-heavy; the core IP strategy is designs + trade marks; JUMBO was involved in notable trade mark disputes; (4) HELLENIC PETROLEUM (now Elvalhalcor, Athens — post-spin-off): oil refining and aluminum processing; ELPE (Hellenic Petroleum) holds process patents for refining and petrochemicals; Elvalhalcor (aluminum rolling, copper/aluminum products) holds manufacturing process patents; (5) INTERAMERICAN / GROUPAMA Insurance (Athens — insurance tech); (6) Tourism: Greece's most significant economic sector (approximately 25% of GDP); tourism IP focuses primarily on: MICE technology platforms; hospitality management software; online travel agencies; (7) SELONDA / NIREUS (fish farming — Mediterranean sea bream [tsipoura] and sea bass [lavraki] aquaculture): marine aquaculture technology patents (net cage design, feeding automation, fish welfare monitoring); stock genetics patents for disease-resistant strains; Greek aquaculture companies have filed some modest patent applications in European aquaculture technology.

No — Greece does not have a general grace period for patent applications. As a member of the European Patent Convention (EPC) since October 7, 1986, Greece applies EPC Article 54's strict absolute novelty standard: any public disclosure of an invention before the filing date (or priority date under Paris Convention) permanently destroys its novelty and makes it unpatentable in Greece. This includes: disclosures made by the inventor — if a Greek inventor presents their invention at a conference, publishes a scientific paper, publicly demos a prototype, gives an investor pitch to a non-confidential audience, or makes any other public disclosure before filing a patent application at OBI (Hellenic Industrial Property Organisation) or as a European Patent application (designating Greece) at the EPO, that disclosure is prior art against their own patent application. There is only one narrow exception under EPC Article 55: a 6-month grace period for disclosures made at officially recognized international exhibitions on the Paris Convention list. Ordinary trade shows, scientific conferences, product launches, and academic publications do NOT qualify for this exception. The practical rule for Greek inventors: a patent application must be filed BEFORE any public disclosure. The Paris Convention priority strategy is the primary tool for Greek inventors who need to file in multiple countries: (1) File a first patent application in any country (e.g., a US provisional application, an OBI Greek national application, or a PCT application); (2) Make any public disclosure (conference, paper, demo); (3) File applications in other countries within 12 months of the first filing, claiming the first filing date as the priority date. Since the priority date predates the disclosure, novelty is preserved. For Greek inventors working on technology with US commercial potential, filing a US provisional application first (before disclosing), and then filing at OBI or EPO within 12 months, is the standard approach. Greek universities and research institutions increasingly have tech transfer offices that advise researchers on this process, but premature public disclosure remains a significant patent rights risk in Greek academic research culture.

Greece controls approximately 20–21% of global merchant shipping capacity by deadweight tonnage (DWT), making Greek-owned fleets the largest national fleet in the world — ahead of Japan (approximately 14%), China (approximately 12%), and Germany (approximately 6%). Understanding why this creates a distinctive IP situation requires distinguishing between fleet ownership and maritime technology development: (1) Why Greece dominates shipping: Greek shipping dominance has historical roots in the island geography of Greece (1,400+ islands, centuries of maritime tradition), the Onassis generation (Aristotle Onassis and Stavros Niarchos built global shipping empires in the 1950s–70s through financial acumen and timing), the open registry system (Greek-owned ships often fly flags of convenience — Liberia, Panama, Marshall Islands, Bahamas — for tax and regulatory benefits), and family-controlled shipping companies with multi-generational expertise (Angelicoussis Group, Tsakos Group, Danaos Corporation, Costamare Inc., Diana Shipping, Safe Bulkers); (2) Greek owners as commercial operators, not technology developers: Greek shipowners are primarily financial operators and logistics managers — they buy vessels (most built in South Korean, Japanese, and Chinese yards), charter them to cargo owners (oil companies, commodity traders, container shipping lines), and manage fleets for maximum commercial return. They typically do NOT develop the underlying marine technology (engines, propulsion, automation, navigation systems) — that is done by European and Asian engineering companies: MAN Energy Solutions (Copenhagen — marine two-stroke diesel engines); Wärtsilä (Helsinki — dual-fuel marine engines, automation, propulsion); Kongsberg Maritime (Kongsberg, Norway — dynamic positioning systems, automation, autonomous vessel technology); ABB Marine (Zürich — electric propulsion, Pod drive systems); GTT (Gaztransport & Technigaz, Paris — LNG membrane containment system patents); (3) GTT and LNG carrier IP — the key maritime patent that Greek LNG owners interact with: GTT (Paris, Euronext listed) holds the foundational patents for LNG membrane containment systems used in virtually all LNG carriers worldwide: Mk III Flex system (corrugated stainless steel primary membrane + polyurethane foam insulation) and No. 96 system (Invar nickel-steel primary membrane + perlite insulation). ALL LNG carrier builders worldwide — Korean (HHIH, Samsung Heavy Industries, DSME/HSHI), Japanese (Kawasaki), Chinese (CSSC/Hudong-Zhonghua) — license GTT's technology at per-vessel fees estimated at $2–6M per LNG carrier. Greek LNG shipowners (Maran Gas Maritime / Angelicoussis Group with ~45 LNG carriers, GasLog/Onassis interests) are the ultimate buyers of this technology — they pay GTT royalties indirectly through their vessel construction contract prices; (4) Where Greek maritime IP does exist: vessel management software (fleet management systems — some Greek companies have developed commercial shipping management software); maritime satellite communication systems (Inmarsat, Starlink Maritime used by Greek fleet operators); Piraeus-based maritime data analytics startups; AIS (Automatic Identification System) data analysis for maritime intelligence (DANAOS Corporation has vessel performance software).

The Athens Local Division is Greece's national local division within the Unified Patent Court (UPC) — the specialized pan-European patent court that became operational on June 1, 2023: (1) Background on the UPC: the UPC is a supranational court that exercises jurisdiction over European patents (validated EP bundle patents and new Unitary Patents) across participating EU member states. Before the UPC, a European patent holder who wanted to enforce their patent against an infringer operating in Greece had to bring litigation in Greek national courts — separately from litigation in Germany, France, or any other EP state. Similarly, a competitor challenging the validity of a European patent had to file revocation actions in each national court separately. The UPC centralizes this litigation; (2) The Athens Local Division: Greek courts, as part of the UPC system, now includes the Athens Local Division. The Athens Local Division can hear: patent infringement actions where the alleged infringement occurs in Greek territory; provisional measures (preliminary injunctions) for infringing acts in Greece; revocation/invalidity actions relating to European patents covering Greece; (3) Unitary Patent in Greece: the Unitary Patent (a new single patent valid across all UPC states, granted by EPO after examination) automatically covers Greece without separate validation at OBI or translation requirements. A patent holder can file one European patent application at EPO, and upon grant, request Unitary Patent status — the patent is then valid in Greece and all other 17+ UPC states simultaneously, with a single annual renewal fee paid to EPO; (4) London Agreement benefit — reduced translation costs in Greece: Greece IS a London Agreement signatory (like Hungary, France, Germany, UK, and many others). For standard European bundle patents (non-Unitary Patents) that the patent holder chooses to validate in Greece: if the EP patent was granted in English by EPO, only a Greek translation of the PATENT CLAIMS (not the full specification) is required for Greek validation. This significantly reduces the cost of obtaining EP patent protection in Greece compared to non-London Agreement states; (5) Greek national IP courts: for utility models, registered designs, trade marks, and Greek national patents (filed at OBI — though most international companies file via EPO/PCT, not OBI), Greek national courts remain the venue. Greek IP litigation has developed significantly since EU IP Enforcement Directive 2004/48/EC implementation; (6) Practical impact for Greece: given that Greece's GDP per capita and R&D investment are relatively modest compared to larger EU economies (Germany, France, Netherlands, Sweden), the volume of patent litigation through the Athens Local Division is expected to be lower than the Munich, Düsseldorf, or Paris local/central divisions — but the Athens Local Division enables Greek patent holders (like Pharmathen for pharmaceutical patents) and international patent holders with Greek infringement to access the UPC system efficiently.

Feta cheese's EU Protected Designation of Origin (PDO) status is a textbook example of how Geographical Indications (GI) can protect a national food product more effectively than patents in contexts where the product is a traditional agricultural commodity: (1) What Feta PDO means: the European Union's Council Regulation 2081/92 (now Regulation 1151/2012 on quality schemes for agricultural products and foodstuffs) established a Protected Designation of Origin system. Under this system, 'Feta' as an EU PDO means: Feta can only be produced in specific Greek regions (Macedonia, Thrace, Epirus, Thessaly, Mainland Greece, Peloponnese, and the island of Lesbos); it must be produced from sheep's milk, or a blend of sheep's and goat's milk (up to 30% goat's milk); the production, processing, and preparation must take place in the designated area; the characteristic taste, texture, and production methods (brining in whey or brine for aging) are specifications tied to the Greek geographical origin; (2) The ECJ case — Denmark and Germany vs. the Commission: when Greece obtained Feta PDO registration in 2002, Denmark (which produces significant quantities of 'Feta'-labeled white brined cheese using cow's milk) and Germany challenged the registration. The European Court of Justice (ECJ) upheld the Feta PDO registration in 2005 (Cases C-465/02 and C-466/02), ruling that: 'Feta' is not a generic name (despite widespread use outside Greece); the name has become so associated with Greek production methods and traditions that it qualifies for PDO status; non-Greek producers must stop using the name 'Feta' for their products. This forced Danish and other European producers to rebrand their white brined cheese; (3) Economic value of Feta PDO: Greek Feta exports generate approximately €350–400 million annually (and the domestic Greek market is substantial — Greeks consume among the world's highest per capita cheese amounts). Without the PDO, global commodity producers using cheaper cow's milk and factory production could capture this market under the same name at lower prices; (4) Why PDO is more appropriate than patent for Feta: a patent on 'Feta production method' would have expired after 20 years; a PDO lasts indefinitely as long as the protected product is produced in the designated area with the specified methods. A patent could not protect a traditional food's geographic origin — the essence of what makes Feta Greek is its origin and traditional production method, not a novel invention. PDO/GI protection is purpose-built for this type of traditional product; (5) Mastiha — the other key Greek GI with biotech potential: Chios Mastiha (the resin of Pistacia lentiscus var. chia trees, produced exclusively on the island of Chios) has both PDO status AND active patent development: the Chios Mastiha Growers Association has worked with Greek universities and research institutions to patent bioactive compound applications of mastiha extract (antibacterial — dental hygiene applications including mastiha toothpaste and chewing gum; anti-inflammatory; cosmeceutical; anti-ulcer effects studied in gastroenterology context). This is a hybrid GI + innovation patent strategy — the PDO protects the geographic origin of the raw material, while patents protect novel applications of its bioactive compounds.

Pharmathen S.A. (Pallini, Attica — private equity owned, formerly listed) represents Greece's most patent-active and internationally focused generic pharmaceutical company, distinguished from other Greek pharma companies by its significant investment in proprietary drug delivery technology R&D: (1) Company overview: Pharmathen was founded in the 1990s and has evolved from a traditional Greek generics manufacturer into a specialty drug delivery technology company. The company was acquired by private equity (BC Partners in 2014 for approximately €250M, then partially recapitalized). Pharmathen employs approximately 700 people and exports to approximately 70 countries; (2) Core IP differentiator — long-acting injectable (LAI) drug delivery: Pharmathen's most significant patent activity is in long-acting injectable (LAI) drug delivery systems — specifically microsphere/microparticle formulation technology for extended-release injectable drugs: the patented technology involves creating biodegradable polymer microspheres (PLGA — poly(lactic-co-glycolic acid) — microspheres loaded with active pharmaceutical ingredient); when injected intramuscularly, the PLGA microspheres degrade slowly over weeks, releasing drug at controlled rates; this eliminates the need for daily oral dosing and improves patient adherence (particularly important for psychiatric patients); Pharmathen has developed long-acting injectable formulations for antipsychotic drugs (risperidone microspheres — a generic to Risperdal Consta [J&J/Janssen's original LAI risperidone product]; the original Risperdal Consta patents were challenged and alternative formulation approaches developed; market-entry timing and specific polymer/drug formulation parameters are the IP battleground for LAI generics); (3) PCT and EPO patent filing: Pharmathen files via PCT (obtaining international filing date) and EPO (for European market protection). This is unusual for a Greek pharmaceutical company — most Greek pharma companies file generic marketing authorization applications but do not file substantive PCT/EPO patent applications on their own formulation innovations; (4) Regulatory strategy: Pharmathen uses the EU's 505(b)(2)-equivalent pathway (hybrid applications referencing innovator data) for novel formulations — CHMP (EMA's Committee for Medicinal Products for Human Use) evaluation; FDA ANDA for the US (where generic versions of Risperdal Consta were pursued by multiple competitors including Pharmathen); (5) Other Greek pharma companies: ELPEN Pharmaceutical (Pikermi — one of Greece's largest by Greek market share; primarily a generics + licensed-in products company; manufacturing process patents but limited formulation innovation patents); VIANEX/DEMO (Egaleo — marketing/manufacturing generics; limited patent activity); GENEPHARM (biosimilar development for EU market via EMA biosimilar pathway); (6) Greek R&D infrastructure: NCSR Demokritos (National Center for Scientific Research, Agia Paraskevi — interdisciplinary; materials science, energy, life sciences; technology transfer office); Foundation for Research and Technology-Hellas (FORTH, Heraklion Crete — photonics, biomedical, cultural heritage research patents).